Taysha Gene Therapies Showcases TSHA-102 Clinical Advancements at IRSF Meeting

One of the key events at the meeting will be the oral presentation titled "Safety and Efficacy Results from the REVEAL Part A Phase 1/2 Trial of TSHA-102 in Pediatric and Adolescent/Adult Cohorts." This presentation is set for June 30, 2026, from 9:00 to 9:20 AM CT, and will be delivered by Dr. Elsa Rossignol, a noted expert in neuroscience and pediatrics from the Université de Montréal. As a principal investigator of the REVEAL trial, Dr. Rossignol is expected to provide critical insights into the safety and efficacy of TSHA-102, a one-time gene therapy aimed at addressing the genetic underpinnings of Rett syndrome.

In addition to the oral presentation, Taysha will feature prominently in several poster presentations throughout the meeting. Notable presentations include:

Additionally, Taysha will host a symposium on July 1, 2026, focusing on the RS-DMA as a primary endpoint for interventional studies.

TSHA-102 is a groundbreaking self-complementary AAV9 gene transfer therapy designed to treat Rett syndrome by delivering a functional form of the MECP2 gene to the CNS. This innovative approach utilizes a novel miRNA-Responsive Auto-Regulatory Element (miRARE) technology, which allows for regulated expression of MECP2 at the cellular level, minimizing the risk of overexpression. Taysha's TSHA-102 has garnered significant regulatory recognition, including Breakthrough Therapy and Fast Track designations from the FDA, highlighting its potential to address a critical unmet medical need in the treatment of Rett syndrome.

Rett syndrome, primarily affecting females, presents a range of debilitating symptoms that include loss of communication, motor impairments, and intellectual disabilities. With no approved therapies that target the root cause of the disease, the urgency for effective treatments has never been greater. Estimates indicate that Rett syndrome impacts approximately 15,000 to 20,000 patients across the U.S., EU, and U.K., showcasing the pressing need for innovative solutions like TSHA-102.

As a clinical-stage biotechnology company, Taysha Gene Therapies is dedicated to advancing AAV-based gene therapies tailored for severe CNS diseases. The company's leadership team brings a wealth of experience in gene therapy development, poised to translate groundbreaking research into life-altering treatments for patients. Taysha’s vision aligns with a commitment to address severe unmet medical needs, aiming to enhance the quality of life for patients and their families.

With the IRSF meeting just days away, attention turns to the insights that Taysha Gene Therapies will bring forth regarding TSHA-102 and its potential to reshape the landscape of treatment for Rett syndrome. The upcoming presentations are set to be a pivotal moment in the ongoing journey toward developing transformative therapies in the realm of gene therapy.